Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 6/20 | 0.53 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 5/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27700149 | 0.95 | RBP4 (0.57) | RBP4CKS1BSKP1SKP2MEN1 | |
| SCHEMBL16836632 | 0.91 | MEN1 (0.53) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL25864436 | 0.89 | RBP4 (0.56) | RBP4CKS1BSKP1SKP2MEN1 | |
| SCHEMBL18087219 | 0.85 | ALDH1A1 (0.57) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL30427482 | 0.84 | RBP4 (0.60) | RBP4MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15921897 | 0.83 | CKS1B (0.55) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL24851165 | 0.82 | MEN1 (0.53) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL10412083 | 0.82 | MEN1 (0.52) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL20042188 | 0.82 | MAPT (0.54) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL30995286 | 0.81 | SLC2A1 (0.46) | RBP4CKS1BSKP1SKP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | RBP4 3238/4885CKS1B 167/4885SKP1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.